Skip to main content
Clinical Trials/NCT01179373
NCT01179373
Completed
Phase 2

Phase 2 Study of Trans Cranial Magnetic Stimulation as Additional Therapy Patients With Alzheimer's Disease

Brainsway1 site in 1 country45 target enrollmentAugust 2010

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Alzheimer's Disease
Sponsor
Brainsway
Enrollment
45
Locations
1
Primary Endpoint
cognitive functioning score by ADAS-COG
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The primary objective of this trial is to assess the ability of Transcranial Magnetic Stimulation with H coil to prefrontal cortex , with an addition of cognitive brain training, to improve cognitive performance in patients with Alzheimer's disease which received drug treatment. This study is a single-center, double-blind 4 months duration trial.

Detailed Description

Primary outcome measure: ADAS-COG (time frame baseline, 2 months, 4 months) Secondary outcome measure: CGI-C,FAB, ADL, Neuropsychological computerized test(time frame baseline, 2 months, 4 months. Estimated enrollment: 40 patients Estimated Study start Date: November 2008 Estimated Study Completion date: November 2009 Number of arms: 2 Ages: 50-85 Genders: both

Registry
clinicaltrials.gov
Start Date
August 2010
End Date
June 2015
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Brainsway
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Men and women aged 50-
  • Diagnosed with Alzheimer's disease for at least one year (by the DSM-IV criteria).
  • Scored below 24 on the MMSE.
  • Received drug therapy for their disease, with each treatment having been administered at an acceptable dosage for at least 5 weeks, with either no effect or only partial response.
  • Answered in the negative to all questions in the pre-TMS treatment safety questionnaire.
  • Gave their oral and written consent to participate in the trial.
  • Exclusion criteria:
  • An additional neurological or psychiatric disorder.
  • Severe personality disorder.
  • Uncontrolled hypertension.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

cognitive functioning score by ADAS-COG

Time Frame: 4 months

Secondary Outcomes

  • Global advancement score by CGI-C(4 months)
  • Frontal lobe functioning score by FAB(4 months)
  • Daily activity score by ADL(4 months)

Study Sites (1)

Loading locations...

Similar Trials